Tag: Investors

11/2/19--Shares of Innovative Industrial Properties (NYSE:IIPR) declined 17.7% in October, according to data from S&P Global Market Intelligence. The stock's return was also negative 17.7%, since no dividends were paid during the month. Innovative Industrial stock's subpar showing in October is being attributed to continued weakness in the overall cannabis sector rather than to company-specific happenings. Read

10/23/19--Russian investors have flocked to the U.S. cannabis industry in recent years. One venture involving associates of Rudy Giuliani drew the scrutiny of federal investigators. Read

8/12/19--Three noted marijuana stocks unveiled their latest quarterly figures last week -- Cronos Group, hemp cannabidiol (CBD) products specialist CV Sciences (OTC: CVSI), and maker of cannabis-based medicine GW Pharmaceuticals. Of the three, GW Pharmaceuticals had the best quarter by a wide margin. Read

8/11/19--According to The Motley Fool writer Keith Speights, Aphria and Charlotte's Web are both good stocks; however, Aphria is an underrated underdog that could be a big winner over the long run, in his view. Charlotte's Web's market share is still under $900 million, but Speights believes it could double over the next few years as the U.S. hemp CBD market shifts into high gear. Read

1/25/19--Benzinga reports news items in the marijuana industry this week. Just to name a few, Acreage Holdings submitted a cannabis-focused PSA to CBS Corporation for the Super Bowl and was rejected. NFL Hall of Famer Joe Montana was part of a group of investors that provided $75 million in venture capital to Caliva. U.S. surgeon general Jerome Adams faced backlash from an anti-marijuana tweet, and speculation about a potential decriminalization of marijuana in the U.S. hit new highs as the government shutdown lingered. Read

12/10/18--Wall Street's top marijuana analyst, Vivien Azer, likes Marlboro maker Altria's $1.8 billion investment in Canadian pot company Cronos Group, telling clients the move represents a "unique entry into cannabis." According Azer, Cronos' emphasis on rare cannabinoids will likely prove valuable for Altria as it looks to diversify from tobacco and into up-and-coming markets like e-cigarettes and marijuana. Read

12/10/18--Barclays, one of the biggest banks in the world, disclosed that it initiated a position in the Canadian marijuana company, Tilray, in the third quarter. It owned 26,319 shares of Tilray stock as of Sept. 30. The company went public in July, and the stock is listed both in Canada and the U.S. Read

12/10/18--The newly public Curaleaf Holdings is attempting to show the world that not all marijuana companies will throw their shareholders under the bus during a rapid expansion process. Between Dec. 12, 2018, and Dec. 12, 2019, it plans to commence share repurchases totaling as much as $50 million, albeit the timing and amount of shares to be repurchased will depend on market conditions and other variables. Read

12/7/18--Shares in Aphria Inc., the third-largest Canadian marijuana company, have crashed over 50% this week because of short-sellers. Since shares have fallen significantly, Aphria's management has taken notice and responded to the allegations calling the short report "a malicious and self-serving attempt to profit by manipulating Aphria's stock price at the expense of Aphria's shareholders." Read

10/6/18--Timothy Collins of Real Money identifies 5 marijuana stocks that offer some diversification or unique features in the legal-weed space: GW Pharma, Canopy Growth, KushCo Holdings, Pyxus International, and CannaRoyalty. Read

9/27/18--The marijuana industry in Canada has exploded, with many Canadian marijuana stocks skyrocketing as well. What's going on now with marijuana in Canada? What threats exist for the marijuana industry? What are the best ways for investors to profit from the rapidly growing marijuana market? The Motley Fool presents everything you need to know about investing in Canadian marijuana stocks. Read

9/11/18--Oklahoma residents looking to invest in the state's upcoming marijuana industry for medical use are anxiously awaiting the passage of business regulations. Many would-be business owners and startup companies are trying to get an early foothold in the this industry by investing in groundwork and business plans, despite no state standards set in stone yet. The medicinal use of marijuana was approved by Oklahoma voters in June. Read

9/11/18--Marijuana stocks offering competitive advantages might prove attractive to investors. Throughout the industry, there are four such niche stocks that bring massive market share potential to the table: CannaRoyalty, Kush Bottles, GW Pharmaceuticals, and Innovative Industrial Properties. Read

9/9/18--Currently, four pure-play marijuana stocks are listed on U.S. stock exchanges, Scotts Miracle-Gro, Canopy Growth Corporation, Cronos Group, and Tilray. According to The Motley Fool writer Keith Speights, Tilray, at least for now, ranks as the marijuana stock that Wall Street likes the most. Tilray is attracting investors' attention because of the potential that it could be the next to land a major deal -- perhaps with Diageo, another big beverage company reportedly looking for a marijuana partner. Read

9/9/18--Three stocks, Canopy Growth, Cronos Group, and Tilray, have rallied sharply since August 14th. These three companies share a common trait in that they are all listed on the NASDAQ or the NYSE. This listing status has attracted traders in the U.S. who have avoided the sector. According to Cannabis industry analyst Alan Brockstein, traders have pushed these three stocks much higher than their peers that don't trade on a major U.S. exchange. Read

9/9/18--Although Canadian marijuana stocks, Aphria Inc. and Aurora Cannabis Inc., have soared over the past month, both stocks are still lower than their levels at the beginning of 2018. Aphria stock has performed better than Aurora so far this year and over the last few weeks. The Motley Fool outlines what needs to be known about how Aphria and Aurora Cannabis stack up against each other in three key areas. Read

8/27/18--Many marijuana stocks experienced significant stock price hikes recently, with notable gains coming last week, and there’s anticipation of even more institutional investors buying into the cannabis industry. For a better sense of what types of investors could be driving the most recent and future market shifts, Pot Network provides an overview of who is currently investing in, or is planning to invest in, a major cannabis stock. Read

8/16/18--Canopy Growth, a Canadian medical marijuana giant, is taking a massive 5 billion Canadian dollar ($3.8 billion) investment and going all in on worldwide medical and recreational cannabis business opportunities, the company’s CEO, Bruce Linton, said during an exclusive, wide-ranging question-and-answer session in Toronto. Constellation Brands – which owns, distributes, and markets 100 beer, wine, and spirits brands, announced this record-setting investment in Canopy Growth, the largest involving a marijuana company to date. Read

8/16/18--Constellation Brands Inc., which for seven decades has made its money off beer, wine and whiskey, sees its future in a marijuana leaf. In the biggest (legal) cannabis deal, the Victor, New York-based beverage company will spend about $3.8 billion to boost its stake in Canadian grower Canopy Growth Corp., betting legalization will gain traction around the world and especially in the U.S. Read

2/27/18--Canadian marijuana producer Cronos Group is the first pot producer and seller to trade on Wall Street. Although other companies with indirect relations to cannabis are trading, this marks a big step for the cannabis industry. Read

1/11/18--Marijuana stocks continued the November rally into December as investors loaded up on stocks ahead of California’s legalized recreational sales. The U.S. Marijuana Index jumped 50% and the Canadian Marijuana Index climbed 65% for the month of December. Read

12/1/17--The pure-play marijuana stock expected to have the highest operating margin on the entire pot industry will likely derive from cannabinoid-based drug developer GW Pharmaceuticals. GW Pharmaceuticals' experimental drug Epidiolex easily found the mark in numerous pivotal-stage clinical trials involving two rare types of childhood-onset epilepsy. If approved, Epidiolex could generate in the neighborhood of $500 million in peak annual sales giving it the highest operating margin of all pot stocks by the end of the decade. Read

8/28/17--Wealthy investors are pouring tens of millions into the cannabis industry in a bid to capitalize on the gold rush that’s expected when California legalizes recreational marijuana on Jan. 1. They’re backing development of new medicinal products, such as cannabis-infused skin patches; new methods for vaporizing and inhaling; and “budtender” apps, which promises to scour 750 strains of cannabis and use lab research, including DNA analysis of each strain, to help customers find the perfect match. Read

6/12/17--Marijuana industry insiders say they have met with TMX Group, the operators of Canada's largest stock exchange, to devise a policy on investing in the U.S., where growing and selling cannabis violates federal laws. However, TMX Group would not confirm that it is holding meetings with the marijuana sector in order to formulate a policy regarding U.S. investments, saying in an email that it does not comment on "individual issuer affairs." Read

5/26/17--Beverly Hills real estate firm Starpoint Properties said it plans to invest $100 million in California marijuana companies over the next 12 months. Starpoint CEO Paul Daneshrad's vehicle for cannabis investing is Stargreen Capital, a subsidiary of the original business drawing on the same assets, investors, and expertise. The firm is looking to invest up to $15 million in companies that, "Have a mindset to really get aggressive and capture market share," Daneshrad said. Read

4/2/17--Although questions and concerns exist about whether or not U.S. Attorney General Jeff Sessions will crack down on marijuana sales in states that have legalized the drug, two marijuana stocks won't be impacted by what Sessions does: Aurora Cannabis and Canopy Growth Corporation. Both stocks are performing well in 2017 so far and appear to be headed much higher. Read

11/20/16--Kyle Kazan, real estate investor and chief executive of Long?Beach-based Beach Front Property Management, Inc., has taken a lead role in creating a fund for those who want a piece of California’s marijuana industry. Kazan anticipates the maturation of the marijuana industry will attract additional investors with business experience, but for now, it’s his view that there is not yet enough capital for all of the potential investment opportunities related to cannabis. Read

11/20/16--According to Brendan Kennedy, CEO of the marijuana-focused private equity firm Privateer Holdings, there's been a surge of interest from investors since the passage of the eight ballot measures. The marijuana market has some unique characteristics that make it attractive to investors, but the big draw is the fledgling legal market for marijuana being around $7 billion, according to New Frontier and ArcView Market Research. Read

11/5/16--Zacks Investment Research has selected four cannabis linked stocks that are poised to benefit from the legalization of marijuana. These stocks also boast a Zacks Rank #1 (Strong Buy) or 2 (Buy): GW Pharmaceuticals,  The Scotts Miracle-Gro Company,  Pepsico, Inc., and Philip Morris International, Inc.. Read

11/4/16--Privateer Holdings, a cannabis-focused private equity firm in Seattle, announced Friday it has closed on $40 million in convertible bridge financing, bringing its fundraising total to $122 million. Privateer said it will use the money to launch new ventures, make strategic acquisitions, and expand its three existing portfolio companies into new markets. Read

10/11/16--Singer Damian Marley, who has opened a massive dispensary in Colorado at Mile High Stadium, is collaborating with Ocean Grown Extracts, and a part of their joint venture is to turn a vacant Coalinga, California prison into a medical marijuana manufacturing plant, which Ocean Grown will use to sell wholesale to dispensaries. Marley’s initial interest was born out of his fondness for Ocean Grown, but the scope and details of the venture came after the two started working together. Read

10/4/16--The Securities and Exchange Commission has filed fraud charges against Infinex Ventures and its CEO Ronald Salem, alleging they falsely claimed to have secured $100 million to finance marijuana businesses. The SEC also claims the company reported more than $500,000 in revenue for the second quarter of 2014, when in reality it didn’t have “any operations, revenue or funding.” Read

9/22/16--On Friday, the editors of the Denver-based Marijuana Business Daily are setting up shop at the Marriott hotel in Center City for what it calls its Crash Course. Eight hours of workshops will offer guidance to aspiring players who want to know how the industry works. Read

9/22/16--Cowen and Company joins the ranks of the few mainstream research firms to officially begin covering the cannabis industry. A comprehensive 100 plus page report with contributions from ten different analysts was issued by Cowen Washington Research Group on September 12. Read

9/16/16--During the Investor Pitch Forum, hosted by the cannabis industry investment and research firm The Arcview Group, some 200 investors Arcview described as “high net worth” met with dozens of companies looking to cash in on the promising new market of legal recreational marijuana. Read